- 全部删除
您的购物车当前为空
Compound SC-1是一种 Sorafenib 的衍生物,可抑制 STAT3磷酸化,通过依赖 SHP-1 的 STAT3失活诱导细胞凋亡,具有抗癌作用。

Compound SC-1是一种 Sorafenib 的衍生物,可抑制 STAT3磷酸化,通过依赖 SHP-1 的 STAT3失活诱导细胞凋亡,具有抗癌作用。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 315 | In stock | |
| 5 mg | ¥ 745 | In stock | |
| 10 mg | ¥ 1,190 | In stock | |
| 25 mg | ¥ 2,530 | In stock | |
| 50 mg | ¥ 3,970 | In stock | |
| 100 mg | ¥ 5,850 | In stock | |
| 200 mg | ¥ 7,890 | In stock | |
| 1 mL x 10 mM (in DMSO) | ¥ 883 | In stock |
1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-(4-cyanophenoxy)phenyl)urea 相关产品
| 产品描述 | Compound SC-1 is a a derivative of the multiple tyrosine kinase inhibitor sorafenib. Compound SC-1 potently inhibits the phosphorylation of STAT3 by blocking STAT3 phosphorylation and activation, and induces apoptosis in hepatocellular carcinoma cell lines[1]. |
| 体外活性 | Compound SC-1(1-10 μM;48 小时;乳腺癌细胞)在所有测试的乳腺癌细胞中都表现出剂量依赖性的细胞活力抑制作用[1]。Compound SC-1(1-10 μM;36 小时;乳腺癌细胞)在乳腺癌细胞系中诱导有效的细胞凋亡活性,同时以剂量依赖的方式下调 p-STAT3 及其下游蛋白 cyclin D1 和 survivin[1] 。 |
| 体内活性 | SC-1在体内MDA-MB-468异种移植瘤中展示了有效的抗肿瘤活性,并下调了p-STAT3[1]。 |
| 动物实验 | Compound SC-1 (10 mg/kg; oral gavage; daily; for 28 days; Female NCr athymic nude mice (4-6 weeks of age) injected with breast cancer cells) treatment shows efficacious antitumor activity and p-STAT3 downregulation in MDA-MB-468 xenograft tumors[1]. |
| 分子量 | 431.8 |
| 分子式 | C21H13ClF3N3O2 |
| CAS No. | 1313019-65-6 |
| Smiles | FC(F)(F)C1=CC(NC(=O)NC2=CC=C(OC3=CC=C(C=C3)C#N)C=C2)=CC=C1Cl |
| 密度 | no data available |
| 颜色 | White |
| 物理性状 | Solid |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 55 mg/mL (127.37 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
评论内容